Labcorp Acquires Select Assets of North Mississippi Health Services’ Ambulatory Outreach Laboratory Business

Labcorp Receives Modern Healthcare’s 2025 Innovators Award

Labcorp Publishes 2024 Corporate Responsibility Report

Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide

New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen)

System advisory re the Crowdstrike computer outage

Genomic landscape of patients with non-small cell lung cancer

Statement regarding Cambodian NHP supply

The November 16, 2022, indictment filed against the Cambodian breeder and Cambodian officials does not name or reference Labcorp.  The Early Development business has multiple global suppliers and requires its vendors to meet high regulatory compliance standards.  Ex-US sites do not use Cambodian NHP supply. The business is working to procure additional supply from other sources for our US operations. US NHP studies comprise less than 2% of overall enterprise Labcorp revenue.  

Labcorp to speak at the Credit Suisse 31st Annual Healthcare conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 31, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference on Tuesday, Nov. 8 , at 1:25 p.m.

Labcorp to speak at the Baird 2022 Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 6, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the Baird 2022 Global Healthcare Conference on Tuesday, Sept. 13 , at 9:05 a.m. ET .

Labcorp to spin off clinical development business

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 28, 2022-- Labcorp (NYSE: LH) (the “Company”), a leading global life sciences company, today announced that its Board of Directors has authorized the Company to pursue a spin-off of the Company’s wholly owned Clinical Development business to Labcorp shareholders through a tax-free transaction.